The preventive phase I trial with the HIV-1 Tat-based vaccine

Vaccine

Volumn 28, Issue 2, 2009, Pages 371-378

  Ensoli, Barbara ^a   Fiorelli, Valeria ^a   Ensoli, Fabrizio ^b   Lazzarin, Adriano ^c   Visintini, Raffaele ^c   Narciso, Pasquale ^d   Di Carlo, Aldo ^b   Tripiciano, Antonella ^a   Longo, Olimpia ^a   Bellino, Stefania ^a   Francavilla, Vittorio ^a   Paniccia, Giovanni ^a   Arancio, Angela ^b   Scoglio, Arianna ^a   Collacchi, Barbara ^a   Ruiz Alvarez, Maria Josè ^a   Tambussi, Giuseppe ^c   Tassan Din, Chiara ^c   Palamara, Guido ^b   Latini, Alessandra ^b   Antinori, Andrea ^d   D'Offizi, Gianpiero ^d   Giuliani, Massimo ^b   Giulianelli, Marina ^d   Carta, Maria ^f   Monini, Paolo ^a   Magnani, Mauro ^e   Garaci, Enrico ^a   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY OF URBINO   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Clinical trials; HIV 1 Tat; Vaccination

Indexed keywords

ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; TAT VACCINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOCHONDRIASIS; IMMUNE RESPONSE; INFORMATION; LEUKOCYTOSIS; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; NEUTROPHILIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TH1 CELL; TH2 CELL; VACCINATION; VOLUNTEER;

ADULT; AIDS VACCINES; EPITOPE MAPPING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; INTERLEUKIN-4; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 70849124014     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.038     Document Type: Article

References (32)

1. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5 (2004) 233-236
2. Srivastava I.K., Ulmer J.B., and Barnett S.W. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev Vaccines 3 (2004) S33-S52
3. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., and Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191 (2005) 654-665
4. Graham B.S., and Mascola J.R. Lessons from failure-preparing for future HIV-1 vaccine efficacy trials. J Infect Dis 191 (2005) 647-649
5. Goldstein G., Manson K., Tribbick G., and Smith R. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). Vaccine 18 (2000) 2789-2795
6. Hinkula J., Svanholm C., Schwartz S., Lundholm P., Brytting M., Engstrom G., et al. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol 71 (1997) 5528-5539
7. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 2 (1996) 960-964
8. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 67 (1993) 277-287
9. Arya S.K., Guo C., Josephs S.F., and Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229 (1985) 69-73
10. Fisher A.G., Feinberg M.B., Josephs S.F., Harper M.E., Marselle L.M., Reyes G., et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature 320 (1986) 367-371
11. Fanales-Belasio E., Moretti S., Nappi F., Barillari G., Micheletti F., Cafaro A., et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 168 (2002) 197-206
12. Gavioli R., Gallerani E., Fortini C., Fabris M., Bottoni A., Canella A., et al. HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 173 (2004) 3838-3843
13. Gavioli R., Cellini S., Castaldello A., Voltan R., Gallerani E., Gagliardoni F., et al. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. Vaccine 26 (2008) 727-737
14. Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A., et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 19 (2001) 2862-2877
15. Rezza G., Fiorelli V., Dorrucci M., Ciccozzi M., Tripiciano A., Scoglio A., et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 191 (2005) 1321-1324
16. Richardson M.W., Mirchandani J., Duong J., Grimaldo S., Kocieda V., Hendel H., et al. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 57 (2003) 4-14
17. Cao J., McNevin J., Holte S., Fink L., Corey L., and McElrath M.J. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 77 (2003) 6867-6878
18. Van Baalen C.A., Schutten M., Huisman R.C., Boers P.H., Gruters R.A., and Osterhaus A.D. Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J Virol 72 (1998) 6851-6857
19. Allen T.M., O'Connor D.H., Jing P., Dzuris J.L., Mothe B.R., Vogel T.U., et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407 (2000) 386-390
20. Maggiorella M.T., Baroncelli S., Michelini Z., Fanales-Belasio E., Moretti S., Sernicola L., et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 22 (2004) 3258-3269
21. Buttò S., Fiorelli V., Tripiciano A., Ruiz-Alvarez M.J., Scoglio A., Ensoli F., et al. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis 188 (2003) 1171-1180
22. Ensoli B., Fiorelli V., Ensoli F., Cafaro A., Titti F., Butto S., et al. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS 20 (2006) 2245-2261
23. Ensoli B., Fiorelli V., Ensoli F., Lazzarin A., Visintini R., Narciso P., et al. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS 22 (2008) 2207-2209
24. Longo O., Tripiciano A., Fiorelli V., Bellino S., Scoglio A., Collacchi B., et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 27 (2009) 3306-3312
25. Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S., et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 5 (1999) 643-650
26. Lindblad E.B. Aluminium adjuvants-in retrospect and prospect. Vaccine 22 (2004) 3658-3668
27. Chang H.C., Samaniego F., Nair B.C., Buonaguro L., and Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11 (1997) 1421-1431
28. Fanales-Belasio E., Moretti S., Fiorelli V., Tripiciano A., Pavone Cossut M.R., Scoglio A., et al. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol 182 (2009) 2888-2897
29. Ensoli B., Barillari G., Salahuddin S.Z., Gallo R.C., and Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345 (1990) 84-86
30. Ferrantelli F., Cafaro A., and Ensoli B. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Curr Opin Biotechnol 15 (2004) 543-556
31. Buonaguro L., Barillari G., Chang H.K., Bohan C.A., Kao V., Morgan R., et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of the inflammatory cytokines. J Virol 66 (1992) 7159-7167
32. Buonaguro L., Buonaguro F.M., Giraldo G., and Ensoli B. The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. J Virol 68 (1994) 2677-2682